Financial reports
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
10-K
2021 FY
Annual report
23 Feb 22
10-Q
2021 Q3
Quarterly report
4 Nov 21
10-Q
2021 Q2
Quarterly report
3 Aug 21
10-Q
2021 Q1
Quarterly report
5 May 21
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
5 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
Current reports
8-K
Entry into a Material Definitive Agreement
5 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
30 Sep 22
8-K
Other Events
23 Sep 22
8-K
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio
8 Aug 22
8-K
Other Events
26 Jul 22
8-K
Other Events
14 Jul 22
8-K
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trial
29 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 22
8-K
New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease
13 Jun 22
8-K
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
10 Jun 22
Registration and prospectus
15-12G
Securities registration termination
17 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
Proxies
DEFA14A
Additional proxy soliciting materials
23 Sep 22
DEFA14A
Additional proxy soliciting materials
12 Sep 22
DEFA14A
Additional proxy soliciting materials
31 Aug 22
DEFM14A
Proxy related to merger
29 Aug 22
DEFA14A
Additional proxy soliciting materials
23 Aug 22
PREM14A
Preliminary proxy related to merger
19 Aug 22
DEFA14A
Additional proxy soliciting materials
18 Aug 22
DEFA14A
Additional proxy soliciting materials
18 Aug 22
DEFA14A
Additional proxy soliciting materials
10 Aug 22
DEFA14A
Additional proxy soliciting materials
8 Aug 22
Other
CT ORDER
Confidential treatment order
7 Mar 19
EFFECT
Notice of effectiveness
28 Oct 16
CORRESP
Correspondence with SEC
25 Oct 16
UPLOAD
Letter from SEC
25 Oct 16
EFFECT
Notice of effectiveness
20 Jun 16
EFFECT
Notice of effectiveness
11 Aug 15
CORRESP
Correspondence with SEC
7 Aug 15
CORRESP
Correspondence with SEC
7 Aug 15
CORRESP
Correspondence with SEC
16 Jul 15
UPLOAD
Letter from SEC
16 Apr 15